Nasopharyngeal Cancer Outcomes at KFSYSCC
Between 2013-2017, the five-year survival rate for nasopharyngeal cancer at KFSYSCC was 86% vs 69% for other hospitals in Taiwan.
Basic Information and Distribution of 2,467 Nasopharyngeal Carcinoma Patients at KFSYSCC from 1990-2019
| Total | 1990-1994 | 1995-1999 | 2000-2004 | 2005-2009 | 2010-2014 | 2015-2019 | |
|---|---|---|---|---|---|---|---|
| n | 2,467 | 82 (3%) | 339 (14%) | 661 (27%) | 573 (23%) | 472 (19%) | 340 (14%) |
| Gender (%) | |||||||
| Male | 1,814 (74%) | 58 (71%) | 250 (74%) | 472 (71%) | 409 (71%) | 369 (78%) | 256 (75%) |
| Female | 653 (26%) | 24 (29%) | 89 (26%) | 189 (29%) | 164 (29%) | 103 (22%) | 84 (25%) |
| Age | |||||||
| Mean/Median | 47/45 | 46/44 | 47/44 | 46/45 | 46/45 | 47/47 | 49/48 |
| Range | 11-90 | 22-76 | 11-86 | 16-90 | 14-81 | 15-80 | 19-90 |
| Q1-Q3 | 39-54 | 37-54 | 38-55 | 39-53 | 39-54 | 39-54 | 40-57 |
| Stage (%) | |||||||
| I | 107 (4%) | 3 (4%) | 15 (4%) | 39 (6%) | 15 (3%) | 19 (4%) | 16 (5%) |
| II | 390 (16%) | 121 (5%) | 33 (10%) | 112 (17%) | 94 (16%) | 82 (17%) | 57 (17%) |
| III | 979 (40%) | 20 (24%) | 111 (33%) | 260 (39%) | 248 (43%) | 193 (41%) | 147 (43%) |
| IV | 853 (35%) | 27 (33%) | 109 (32%) | 206 (31%) | 214 (37%) | 178 (38%) | 119 (35%) |
| Unknown | 138 (6%) | 20 (24%) | 71 (21%) | 44 (7%) | 2(0.4%) | 0 (0%) | 1(0.3%) |
Based on KFSYSCC's cancer registry from 1990 to 2019, there were 2,467 analytic nasopharyngeal carcinoma cases, with 1,814 males (74%) and 653 females (26%). The average and median ages were 47 and 45 years old, respectively; the youngest patient was 11 years old, and the oldest was 90 years old; the interquartile range (Q1-Q3) was 39-54. By stage, there were 107 stage I patients (4%), 390 stage II patients (16%), 979 stage III patients (40%), and 853 stage IV patients (35%). The table below presents the basic patient information and stage distribution, categorized by the year of diagnosis.
Survival Curves for 2,467 Nasopharyngeal Carcinoma Patients at KFSYSCC from 1990-2019
From 1990 to 2019, the chart below illustrates the five-year observed survival rates for 2,467 nasopharyngeal carcinoma patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for nasopharyngeal carcinoma increased from 65% in 1990-1994 to 85% in 2015-2019, while the ten-year survival rate rose from 56% in 1990-1994 to 69% in 2010-2014.
Treatment Methods and Stages for 340 Nasopharyngeal Carcinoma Patients by Stage (2015-2019)
| Treatment Type | Total | Stage I | Stage II | Stage III | Stage IV | Unknown |
|---|---|---|---|---|---|---|
| Total | 340 | 16 | 57 | 147 | 119 | 1 |
| Surgical Treatment | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Radiation Therapy | 328 (96%) | 16 (100%) | 57 (100%) | 147 (100%) | 107 (90%) | 1 (100%) |
| Chemotherapy | 329 (97%) | 9 (56%) | 56 (98%) | 147 (100%) | 116 (97%) | 1 (100%) |
| Targeted Therapy | 1 (0.3%) | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) |
| Hormone Therapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Immunotherapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Palliative Care | 9 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (8%) | 0 (0%) |
| Bone Marrow/Stem Cell Transplant | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| No Record of Initial Treatment Reported | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Between 2015 and 2019, there were a total of 340 analytic nasopharyngeal carcinoma cases, including 16 patients in stage I, 57 in stage II, 147 in stage III, and 119 in stage IV. In terms of treatment methods, 328 (96%) received radiation therapy, 329 (97%) underwent chemotherapy, 1 (0.3%) received targeted therapy, and 9 (3%) underwent palliative care.
Five-Year Survival Rates of 340 Nasopharyngeal Carcinoma Patients by Stage (2015-2019)
KFSYSCC’s 2015-2019 five-year observed survival rates for 340 nasopharyngeal carcinoma patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 70% for stage 1, 98% for stage 2, 91% for stage 3, and 70% for stage 4.